论文部分内容阅读
目的观察散结通络方联合放疗治疗肺癌脑转移的临床疗效。方法将76例肺癌脑转移患者随机分为治疗组与对照组,每组38例。治疗组放疗后予散结通络方口服,对照组予单纯放疗及对症治疗。两组疗程均为6个月,观察临床疗效及无进展生存期(PFS),比较肿瘤标志物水平(CEA、CA50、CA199、CA125)及免疫功能指标(NK、CD3+、CD4+、CD8+、CD4+/CD8+)的变化情况。结果 1治疗组、对照组临床总有效率分别为94.74%和89.47%;组间临床疗效比较,差异无统计学意义(P>0.05)。2疗程期间,治疗组、对照组中位PFS分别为5.67个月和3.29个月,组间中位PFS比较差异有统计学意义(P<0.05)。3组间治疗后比较,CEA、CA50、CA125水平差异有统计学意义,治疗组低于对照组(P<0.05)。4组间治疗后比较,NK水平差异有统计学意义,治疗组高于对照组(P<0.05)。结论散结通络方联合放疗治疗肺癌脑转移,可显著抑制脑转移瘤生长,延长无进展生存期,改善患者免疫功能。
Objective To observe the clinical efficacy of Sanjie Tongluo combined with radiotherapy in the treatment of brain metastases of lung cancer. Methods 76 patients with brain metastases of lung cancer were randomly divided into treatment group and control group, with 38 cases in each group. After radiotherapy, the treatment group was given Sanjie Tongluo Oral, and the control group was treated with radiotherapy alone and symptomatic treatment. The two groups were treated for 6 months. The clinical efficacy and progression-free survival (PFS) were observed. The levels of tumor markers (CEA, CA50, CA199, CA125) and immune function indexes (NK, CD3 +, CD4 +, CD8 + CD8 +) changes. Results The total clinical effective rates in the treatment group and the control group were 94.74% and 89.47%, respectively. There was no significant difference in clinical efficacy between the two groups (P> 0.05). Median PFS in treatment group and control group were 5.67 months and 3.29 months, respectively. There was significant difference in PFS between two groups (P <0.05). After treatment, the levels of CEA, CA50 and CA125 in the three groups were significantly different from those in the control group (P <0.05). After treatment, the levels of NK in the four groups were significantly different, the treatment group was higher than the control group (P <0.05). Conclusion San Jie Tong Luo Fang combined with radiotherapy for lung cancer brain metastasis can significantly inhibit the growth of brain metastases, prolong progression-free survival and improve immune function.